Global Neuropathy Screening Devices Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Neuropathy Screening Devices Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Neuropathy can develop in many diseases and disorders. Nerve damage may occur in a single location or be widely distributed. It may mainly affect sensory nerves, motor nerves, autonomic nerves or many types of nerves. Any substance that damages nerves will interfere with its ability to transmit accurate signals, resulting in many signs and symptoms.

Neuropathy Screening Devices mainly screen patients for vibration, temperature and pressure sensitivity. It also includes some imaging examination equipment and electromyography equipment, etc.

Market Overview:

The latest research study on the global Neuropathy Screening Devices market finds that the global Neuropathy Screening Devices market reached a value of USD 80.84 million in 2022. It’s expected that the market will achieve USD 113.31 million by 2028, exhibiting a CAGR of 5.79% during the forecast period.

Short-term Impact

The new coronavirus has been considered a pandemic by the World Organization, and few countries can escape its effects. At present, the world's major consumer and production countries, such as the United States, Germany, the United Kingdom, and so on, are all trapped in the mire. Although isolation measures were not taken immediately in order not to affect economic development, the growing severity of the epidemic has affected the normal production of enterprises, as well as consumption, imports and exports between countries. The main consumption areas of Neuropathy Screening Devices are some countries in Europe and US, which are also the hardest hit areas of the current epidemic. It is expected that the sales volume of Neuropathy Screening Devices will not grow too much.
Most agents selling neuropathy screening equipment have changed their business hours or services. With the epidemic becoming more and more serious, some areas have adopted the strategy of city closure, and people's travel has decreased, resulting in a decline in offline passenger flow. Advantages of online sales model are highlighted. The offline retail of Nervous Screening Devices Industry equipment encountered challenges during the outbreak of Covid-19.
Because most enterprises in the market are located in the United States, Europe and other areas affected by the epidemic. With the change of office mode, home office has become the mainstream. In the supply, distribution, manufacturing and quality links, improve the safety and hygiene standards and strict protection standards to ensure the quality and safety of products. The epidemic situation promoted the improvement of safety standards of Neuropathy Screening Devices.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Owen Mumford is one of the major players operating in the Neuropathy Screening Devices market, holding a share of 23.11% in 2021.

Owen Mumford is a global leader in medical device design and manufacture, leading innovation in this space and delivering medical device solutions that respond to customer and market needs. For almost 70 years Owen Mumford have collaborated with pharmaceutical, biotechnology and diagnostic companies, medical distributors, healthcare professionals and patients. Through this well-established network Owen Mumford deliver the highest levels of safety, comfort and accuracy in the treatment and diagnosis of chronic diseases such as rheumatoid arthritis, diabetes and multiple sclerosis.

Impeto Medical SAS is a privately owned medical device company formed in June 2005. Its corporate headquarters are located in Paris, France. Two subsidiaries have been created: Beijing Impeto Medical in China and Impeto Medical Inc. in San Diego, U.S. Provide screening tests for the medical community to deal with epidemic metabolic diseases and their complications.

Segmentation Overview:

Among different product types, Sensory segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Neuropathy Screening Devices market covered in Chapter 3:

Owen Mumford
Trigocare International Gmbh
NeuroMetrix
Prosenex
Mediracer Ltd
Impeto Medical
Beijing Oerhuatai Technology
Medical Monofilament Manufacturing, llc
Phi Med Europe

In Chapter 4 and Chapter 14.2, on the basis of types, the Neuropathy Screening Devices market from 2018 to 2029 is primarily split into:

Thermal
Sensory
Sudomotor
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Neuropathy Screening Devices market from 2018 to 2029 covers:

Hospitals
Clinics
Diagnostic Centers
Drug Stores

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)